Antengene Corporation Limited
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of Treating Patients Beyond Borders. Since 2017, Antengene has built a broad and expanding pipeline of 13 clinical and pre-clinical assets. Antengene has global rights on 10 assets, and Asia Pacific rights, including the Greater China region, on 3 assets. We have successfully obtained marketing authorizations for selinexor, Antengene’s lead asset, in multiple Asia Pacific counties and regions including mainland China, Taiwan,China, South Korea, Singapore, and Australia.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
About us
Developing innovative cancer medicines to treat patients beyond borders worldwide.
Our Mission
Building fully-integrated capabilities in discovery, clinical development, manufacturing and commercialization to foster the rapid clinical adoption of innovative medicines from around the world for the benefit of broad patient populations
Corporate Social Responsibility
Antengene is committed to fulfilling its corporate social responsibility by introducing novel and innovative oncology therapies for cancer patients and strives to discover new medical solutions to improve public health.
We have worked closely with key stakeholders from all parts of our community, including government agencies, healthcare providers, and non-profit organizations, to benefit more patients.